Cargando…

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, prevents renal glucose reabsorption resulting in urinary glucose excretion. This open‐label, parallel cohort, randomized study conducted in healthy Chinese adults residing in China assessed the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yinhua, Mu, Yuting, Shi, Haihong, Liang, Yali, Liu, Zeyuan, Matschke, Kyle, Hickman, Anne, Krishna, Rajesh, Sahasrabudhe, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003779/ https://www.ncbi.nlm.nih.gov/pubmed/30934166 http://dx.doi.org/10.1002/cpdd.686

Ejemplares similares

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States
por: Dawra, Vikas Kumar, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Fediuk, Daryl J., et al.
Publicado: (2019)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022)

Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
por: Raje, Sangeeta, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
por: Callegari, Ernesto, et al.
Publicado: (2020)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Overview of Ertugliflozin
por: Nguyen, Vivianne K., et al.
Publicado: (2019)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy
por: Croteau, Dominique, et al.
Publicado: (2023)

1575 A 28-day high-dose safety and pharmacokinetics study of raltegravir in healthy subjects
por: Krishna, Rajesh, et al.
Publicado: (2014)

Ertugliflozin for type 2 diabetes [Correction]
Publicado: (2019)

Role of Ertugliflozin in the Management of Diabetes Mellitus
por: Totade, Manisha, et al.
Publicado: (2022)

The Effect of a High-Fat Breakfast on the Pharmacokinetics of Moxidectin in Healthy Male Subjects: A Randomized Phase I Trial
por: Korth-Bradley, Joan M., et al.
Publicado: (2012)

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
por: Liu, Jie, et al.
Publicado: (2020)

Ertugliflozin in the treatment of type 2 diabetes mellitus
por: Marrs, Joel C, et al.
Publicado: (2020)

Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations
por: Tarabar, Sanela, et al.
Publicado: (2020)

Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects
por: Smithline, Howard A, et al.
Publicado: (2012)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
por: Xu, Huiping, et al.
Publicado: (2021)

Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis
por: Wu, Hailan, et al.
Publicado: (2021)

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
por: Patel, Shrita, et al.
Publicado: (2020)

Single dose pharmacokinetic equivalence study of two gabapentin preparations in healthy subjects
por: Tjandrawinata, Raymond R, et al.
Publicado: (2014)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2018)

Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects
por: Wu, Guolan, et al.
Publicado: (2020)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
por: Sheng, Lei, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
por: Wang, Yu, et al.
Publicado: (2022)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mgveh5rhit9kkinkmoqm27hppv